IL2 and rheumatoid arthritis: In the current study, we found that low dose IL‐2 could also suppress osteoclastogenesis in RA by inhibiting receptor activator of nuclear factor‐κB ligand (RANKL) effect via c‐Jun N‐terminal kinase (JNK) pathway.